PDS Biotechnology (PDSB) vs Rallybio (RLYB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Rallybio (RLYB) has outperformed PDS Biotechnology (PDSB) over the past year, gaining 284.7% versus a gain of 40.0%. Over five years, RLYB leads with a -86.3% price change compared with -88.8% for PDSB. PDS Biotechnology is the larger company by market cap ($100.0 million vs $90.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PDSB | RLYB |
|---|---|---|
| Share price | $1.38 | $17.02 |
| Market cap | $100.01M | $90.42M |
| 1-day change | +35.29% | +0.18% |
| YTD return | +79.22% | +210.13% |
| 1-year return | +39.96% | +284.72% |
| 5-year return | -88.81% | -86.29% |
| P/E ratio (TTM) | — | 2.12 |
| EPS (TTM) | $-0.64 | $8.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.55 | $17.57 |
| 52-week low | $0.195 | $3.67 |
| Distance from 52-week high | -10.97% | -3.15% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +262.32% | — |
| Average volume | 23.24M | 21.33K |
| Shares outstanding | 72.47M | 5.31M |
| Employees | 21 | 7 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RLYB has outperformed PDSB by 244.8 percentage points over the past year.
About PDS Biotechnology
PDSB stock →PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
About Rallybio
RLYB stock →Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
PDSB vs RLYB FAQ
Which is bigger, PDS Biotechnology or Rallybio?
PDS Biotechnology (PDSB) is larger, with a market capitalization of $100.01M compared with $90.42M for Rallybio (RLYB).
Which stock has performed better over the past year, PDSB or RLYB?
RLYB returned +284.72% over the past 12 months, compared with +39.96% for PDSB (price return, excluding dividends). Past performance does not predict future results.
Are PDS Biotechnology and Rallybio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.